Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 636-639

  Houghton, Peter J ^a   Kang, Min H ^b   Reynolds, C Patrick ^b   Morton, Christopher L ^c   Kolb, E Anders ^d   Gorlick, Richard ^e   Keir, Stephen T ^f   Carol, Hernan ^g   Lock, Richard ^g   Maris, John M ^h   Billups, Catherine A ^c   Smith, Malcolm A ⁱ  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Preclinical testing; SMAC mimetic

Indexed keywords

ANTINEOPLASTIC AGENT; LCL 161; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOMA; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGOPEPTIDES; PEPTIDOMIMETICS; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863154799     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23167     Document Type: Article

References (23)

1. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988-994.
2. Gyrd-Hansen M, Meier P. IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
3. Chai J, Du C, Wu JW, et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406: 855-862.
4. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
5. Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408: 1004-1008.
6. Srinivasula SM, Hegde R, Saleh A, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112-116.
7. Gaither A, Porter D, Yao Y, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007; 67: 11493-11498.
8. Varfolomeev E, Goncharov T, Fedorova AV, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-24299.
9. Mahoney DJ, Cheung HH, Mrad RL, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105: 11778-11783.
10. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
11. Zawel LS, Straub C, Firestone B, et al. Therapeutic targeting of inhibitor of apoptosis proteins. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research 2010 Abstr #138.
12. Weisberg E, Ray A, Barrett R, et al. Smac mimetics: Implications for enhancement of targeted therapies in leukemia. Leukemia 2010; 24: 2100-2109.
13. Infante JR, Dees EC, Burris HA, et al. A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research 2010 Abstr #2775.
14. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
15. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 37-45.
16. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models andearly testing results. Pediatr Blood Cancer 2006.
17. Keir ST, Morton CL, Billups C, et al. Initial testing of VNP 4010 1M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51: 439-441.
18. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
19. Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-4426.
20. Petersen SL, Wang L, Yalcin-Chin A, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456.
21. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008; 14: 4572-4583.
22. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004; 305: 1471-1474.
23. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.